John J. Crowley

28.7k total citations · 7 hit papers
195 papers, 17.8k citations indexed

About

John J. Crowley is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John J. Crowley has authored 195 papers receiving a total of 17.8k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 89 papers in Pulmonary and Respiratory Medicine and 43 papers in Molecular Biology. Recurrent topics in John J. Crowley's work include Lung Cancer Treatments and Mutations (63 papers), Lung Cancer Research Studies (57 papers) and Lung Cancer Diagnosis and Treatment (38 papers). John J. Crowley is often cited by papers focused on Lung Cancer Treatments and Mutations (63 papers), Lung Cancer Research Studies (57 papers) and Lung Cancer Diagnosis and Treatment (38 papers). John J. Crowley collaborates with scholars based in United States, Canada and United Kingdom. John J. Crowley's co-authors include Kathy S. Albain, Charles A. Coltman, Joseph M. Unger, Robert B. Livingston, David R. Gandara, Peter Goldstraw, Laura F. Hutchins, Kari Chansky, Michael LeBlanc and Bart Barlogie and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Neuron.

In The Last Decade

John J. Crowley

190 papers receiving 17.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International Staging System for Multiple Myeloma

2005 1.9k citations John J. Crowley, Bart Barlogie et al. Journal of Clinical Oncology profile →
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter

2004 1.7k citations Ian M. Thompson, Phyllis J. Goodman et al. profile →
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials

1999 1.7k citations Joseph M. Unger, John J. Crowley et al. profile →
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 768 citations John J. Crowley et al. Journal of Clinical Oncology profile →
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

1995 633 citations Kathy S. Albain, Valerie W. Rusch et al. Journal of Clinical Oncology profile →
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

1991 607 citations Kathy S. Albain, John J. Crowley et al. Journal of Clinical Oncology profile →
The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer

2009 370 citations Kari Chansky, John J. Crowley et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by John J. Crowley

Since Specialization

Citations

This map shows the geographic impact of John J. Crowley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Crowley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Crowley more than expected).

Fields of papers citing papers by John J. Crowley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Crowley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Crowley. The network helps show where John J. Crowley may publish in the future.

Co-authorship network of co-authors of John J. Crowley

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Crowley. A scholar is included among the top collaborators of John J. Crowley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Crowley. John J. Crowley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cure Models as a Useful Statistical Tool for Analyzing Survival 2012 ·Clinical Cancer Research ·Megan Othus, Bart Barlogie, Michael LeBlanc, John J. Crowley	151
2	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 2012 ·Clinical Cancer Research ·Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, David R. Gandara	38
3	Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial 2010 ·Journal of Clinical Oncology ·Katherine M.W. Pisters, Eric Vallières, John J. Crowley, Wilbur A. Franklin, Paul A. Bunn, Robert J. Ginsberg, Joe B. Putnam, Kari Chansky, David R. Gandara	167
4	Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023 2008 ·Journal of Clinical Oncology ·Karen Kelly, Kari Chansky, Laurie E. Gaspar, Kathy S. Albain, James R. Jett, Yee Ung, Derick Lau, John J. Crowley, David R. Gandara	421
5	The Impact of Additional Prognostic Factors on Survival and their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition 2008 ·Journal of Thoracic Oncology ·Jean‐Paul Sculier, Kari Chansky, John J. Crowley, Jan P. van Meerbeeck, Peter Goldstraw	268
6	Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 2007 ·Journal of Thoracic Oncology ·Wallace Akerley, Jason McCoy, Paul J. Hesketh, J. Wendall Goodwin, James D. Bearden, James N. Atkins, Kari Chansky, John J. Crowley, David R. Gandara	7
7	108 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Laurie E. Gaspar, J. McCoy, Karen Kelly, Kathy S. Albain, John J. Crowley, David R. Gandara	5
8	The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer 2006 ·Journal of Thoracic Oncology ·Peter Goldstraw, John J. Crowley	96
9	Distinct Structural Features of Phospholipids Differentially Determine Ethanol Sensitivity and Basal Function of BK Channels 2005 ·Molecular Pharmacology ·John J. Crowley, Steven N. Treistman, Alejandro M. Dopico	33
10	Estimated impact of the Prostate Cancer Prevention Trial on population mortality 2005 ·Cancer ·Joseph M. Unger, Ian M. Thompson, Michael LeBlanc, John J. Crowley, Phyllis J. Goodman, Leslie G. Ford, Charles A. Coltman	26
11	Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study 2005 ·Annals of Oncology ·Howard West, John J. Crowley, Ralph Vance, Wilbur A. Franklin, Robert B. Livingston, Shaker R. Dakhil, Jeffrey K. Giguere, Saul E. Rivkin, Michael Kraut, Kari Chansky, David R. Gandara	54
12	Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003) 2003 ·Seminars in Oncology ·Madhav V. Dhodapkar, Joth Jacobson, Morie A. Gertz, John J. Crowley, Bart Barlogie	50
13	Induction paclitaxel/carboplatin in early stage non-small cell lung cancer 1997 ·Seminars in Oncology ·Katherine M.W. Pisters, Mark G. Kris, Paul A. Bunn, David H. Johnson, John C. Ruckdeschel, John J. Crowley, Robert J. Ginsberg	2
14	Congenital pancreatic pseudocyst: A rare cause of abdominal mass in a neonate 1996 ·Pediatric Radiology ·John J. Crowley, William H. McAlister	5
15	Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study 1995 ·Investigational New Drugs ·Stephen K. Williamson, John J. Crowley, Robert B. Livingston, Timothy J. Panella, J. Wendall Goodwin	17
16	Neoadjuvant therapy: A novel and effective treatment for stage IIIb non-small cell lung cancer 1994 ·The Annals of Thoracic Surgery ·John J. Crowley, Valerie W. Rusch, Kathy S. Albain, Thomas W. Rice, Vassyl A. Lonchyna, Robert J. McKenna, K. Stelzer, Robert B. Livingston	65
17	Prolonged, alternating chemotherapy for extensive small cell lung cancer. A southwest oncology group study 1993 ·Cancer ·Robert B. Livingston, (unknown), John J. Crowley, Stephen K. Williamson, Frederick J. Meyers, Timothy J. O’Rourke, John R. Neefe	3
18	Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy 1993 ·Journal of Thoracic and Cardiovascular Surgery ·Valerie W. Rusch, Kathy S. Albain, John J. Crowley, Thomas W. Rice, Vassyl A. Lonchyna, Robert J. McKenna, Robert B. Livingston, Brian R. Griffin, John R. Benfield	128
19	Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma 1991 ·Investigational New Drugs ·Ralph Vance, John J. Crowley, John S. Macdonald, Frederick R. Ahmann	1
20	Effects of radiation type and dose and the role of glucocorticoids, gonadectomy, and thyroidectomy in mammary tumor induction in mammotropin-secreting pituitary tumor-grafted rats. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Kelly H. Clifton, John J. Crowley	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact